NCT01660737已完成不适用
Observational Study With PASCALLERG ® in Patients With Hay Fever
Pascoe Pharmazeutische Praeparate GmbH1 个研究点 分布在 1 个国家目标入组 123 人开始时间: 2012年2月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 123
- 试验地点
- 1
- 主要终点
- Efficacy of Pascallerg
研究概览
简要总结
The aim of this observational study is to document the therapeutic use of PASCALLERG ® for hay fever. Based on the survey is a decrease in disease-specific symptoms when taking PASCALLERG ® over a period of 4 weeks will be documented. In addition to the compatibility can be assessed.
详细描述
There are documented male and female patients over the age of one year who suffer from hay fever. The traetment time is about a period of 4 weeks with PASCALLERG® tablets.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hay fever
排除标准
- •Lactose intolerance and / or
- •Chromium hypersensitivity
结局指标
主要结局
Efficacy of Pascallerg
时间窗: appr. 4 weeks after baseline (after appr. 4 weeks of treatment)
Request of Efficacy using a 4-stage scale (very good efficacy, good efficacy, moderate efficacy, no efficacy)
Tolerability of Pascallerg
时间窗: app. 4 weeks after baseline (treatment app. for 4 weeks)
Request of Tolerability using a 2-stage scale (very good tolerability, bad tolerability)
次要结局
- Change of Symptom Bronchial Complaints (Pre-post)(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
- Change of Symptom Headache (Pre-post)(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
- Change of Symptom Tearing Eyes (Pre-post)(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
- Change of Symptom Dry Eyes (Pre- Post)(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
- Change of Symptom Itching Eyes (Pre- Post)(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
- Change of Symptom Rhinitis (Pre-post)(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
- Numerical Rating Scale Well Beeing (Pre- Post)(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
- Change of Symptom Burning Eyes (Pre-post)(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
- Change of Symptom Sneezing (Pre-post)(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
- Change of Symtom Fatigue / Tiredness(Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Safety and Technical Performance of Plastalgin and Plastalgin Fast in Patients Requiring a Dental ImpressionDental MalocclusionEdentulous MouthDental MisalignmentNCT05614635Septodont59
暂停
不适用
Paclitaxel Therapeutic Drug Monitoring in Cancer PatientsSolid Tumor, AdultMetastatic Nonsmall Cell Lung CancerAnatomic Stage IV Breast Cancer AJCC v8Metastatic Cervical CarcinomaMetastatic Ovarian CarcinomaMalignant Uterine NeoplasmMetastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8Recurrent Breast CarcinomaRecurrent Cervical CarcinomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Ovarian CarcinomaRecurrent Vulvar CarcinomaStage IV Cervical Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Vulvar Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVA Ovarian Cancer AJCC v8Stage IVA Vulvar Cancer AJCC v8Stage IVB Cervical Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Stage IVB Ovarian Cancer AJCC v8Stage IVB Vulvar Cancer AJCC v8Vulva Squamous Cell CarcinomaVulvar CancerInvasive Breast CancerNCT03987555Wake Forest University Health Sciences55
进行中（未招募）
2 期
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic LymphomaLymphoblastic LymphomaAcute Lymphoblastic LeukemiaNCT01574274Dana-Farber Cancer Institute240
Unknown
不适用
Plaqenil Role in Prevention of Age Related Macular DegenerationAge Related Macular DegenerationNCT01541449Ziv Hospital30
已完成
3 期
Evaluate Dental Plaque Benefit of a Preventive Treatment GelDental PlaqueNCT03546491Procter and Gamble32